Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Astellas’ LLP Sale to Private Equity Group Signals New Business Model for Older Drugs
April 10, 2017
-
BUSINESS Boehringer Japan to Spur Joint Drug Discovery Research, Eyes 1st Clinical Trial in 2020
April 7, 2017
-
BUSINESS Actelion’s Flolan Generic Outstrips Originator in Pediatric Use with Rare Dosage Nod; Japan Chief Says Company Fulfilling Maker’s Responsibility
April 6, 2017
-
INTERVIEW Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO
April 5, 2017
-
REGULATORY “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
-
REGULATORY MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
-
BUSINESS EA Pharma Eager to Roll Out Several New Drugs in Next Couple of Years
April 3, 2017
-
TRENDS Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
-
BUSINESS Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
-
BUSINESS Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
March 29, 2017
-
ORGANIZATION Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
-
ORGANIZATION Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
-
BUSINESS Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
-
TRENDS As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
-
BUSINESS Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
-
ORGANIZATION Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
-
BUSINESS Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
-
BUSINESS Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
-
REGULATORY Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
-
BUSINESS Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…